Work

Evaluation Of The Novel, Orally Bioavailable Selective Inhibitor Of Nuclear Export (SINE) Verdinexor (KPT-335) In Spontaneous Canine Cancer: Results Of Phase I and Phase II Clinical Trials

Year: 2013

Type: article

Source: Blood

DOI: 10.1182/blood.v122.21.5149.5149

Authors: Cheryl London, Luis feo Bernabe, Sandra Barnard, William Kisseberth, Antonella Borgatti, Michael Henson, Heather Wilson, Kiersten Jensen, Daisuke Ito, Jaime Modiano, Misty Bear, Michael Pennell, Jean-Richard Saint-Martin, Dilara McCauley, Sharon Shacham, Michael Kauffman

Institutions: The Ohio State University, University of Minnesota, Texas A&M University, Karyopharm Therapeutics (United States)

Language: English

Topic: Veterinary Oncology Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2268628675

FWCI:

Cites:

Cited by: 2

Related to: 10